Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Makiko Hayashi

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Biorxiv : the Preprint Server for Biology|May 10, 2023
Metabolic Reprogramming by Histone Deacetylase Inhibition Selectively Targets NRF2-activated tumorsDimitris Karagiannis, Warren Wu, Albert Li, et al.
Cell Reports|January 2, 2024
Metabolic reprogramming by histone deacetylase inhibition preferentially targets NRF2-activated tumorsDimitris Karagiannis, Warren Wu, Albert Li, et al.
American Journal of Human Genetics|August 26, 2014
A mutation of COX6A1 causes a recessive axonal or mixed form of Charcot-Marie-Tooth diseaseGen Tamiya, Satoshi Makino, Makiko Hayashi, et al.
Nature|February 19, 2025
Cooperative nutrient scavenging is an evolutionary advantage in cancerGizem Guzelsoy, Setiembre D Elorza, Manon Ros, et al.
Biorxiv : the Preprint Server for Biology|May 4, 2026
Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancerWen-Hsuan Chang, Alec J Vaughan, Addison G Stamey, et al.
Cell Metabolism|February 25, 2023
NRF2 activation induces NADH-reductive stress, providing a metabolic vulnerability in lung cancerTommy Weiss-Sadan, Maolin Ge, Makiko Hayashi, et al.
Cell Reports|October 27, 2023
KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistanceAnastasia-Maria Zavitsanou, Ray Pillai, Yuan Hao, et al.
Science Advances|March 27, 2024
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in <i>KEAP1</i> mutant lung cancerRay Pillai, Sarah E LeBoeuf, Yuan Hao, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2023
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in <i>KEAP1</i> mutant lung cancerRay Pillai, Sarah E LeBoeuf, Yuan Hao, et al.
Biorxiv : the Preprint Server for Biology|July 28, 2023
Tumor-intrinsic LKB1-LIF signaling axis establishes a myeloid niche to promote immune evasion and tumor growthAli Rashidfarrokhi, Ray Pillai, Yuan Hao, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Biorxiv : the Preprint Server for Biology|May 10, 2023
Metabolic Reprogramming by Histone Deacetylase Inhibition Selectively Targets NRF2-activated tumorsDimitris Karagiannis, Warren Wu, Albert Li, et al.
Cell Reports|January 2, 2024
Metabolic reprogramming by histone deacetylase inhibition preferentially targets NRF2-activated tumorsDimitris Karagiannis, Warren Wu, Albert Li, et al.
American Journal of Human Genetics|August 26, 2014
A mutation of COX6A1 causes a recessive axonal or mixed form of Charcot-Marie-Tooth diseaseGen Tamiya, Satoshi Makino, Makiko Hayashi, et al.
Nature|February 19, 2025
Cooperative nutrient scavenging is an evolutionary advantage in cancerGizem Guzelsoy, Setiembre D Elorza, Manon Ros, et al.
Biorxiv : the Preprint Server for Biology|May 4, 2026
Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancerWen-Hsuan Chang, Alec J Vaughan, Addison G Stamey, et al.
Cell Metabolism|February 25, 2023
NRF2 activation induces NADH-reductive stress, providing a metabolic vulnerability in lung cancerTommy Weiss-Sadan, Maolin Ge, Makiko Hayashi, et al.
Cell Reports|October 27, 2023
KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistanceAnastasia-Maria Zavitsanou, Ray Pillai, Yuan Hao, et al.
Science Advances|March 27, 2024
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in <i>KEAP1</i> mutant lung cancerRay Pillai, Sarah E LeBoeuf, Yuan Hao, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2023
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in <i>KEAP1</i> mutant lung cancerRay Pillai, Sarah E LeBoeuf, Yuan Hao, et al.
Biorxiv : the Preprint Server for Biology|July 28, 2023
Tumor-intrinsic LKB1-LIF signaling axis establishes a myeloid niche to promote immune evasion and tumor growthAli Rashidfarrokhi, Ray Pillai, Yuan Hao, et al.
Pageof 5